Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19
Rosie S Jones, Patricia S Smith, Paul H Berg, Amparo De La Peña, Paul P Cook, Imad Shawa, Kathleen M Kioussopoulos, Yu Hu, Robert J Schott
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484221119316
BACKGROUND: Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring mechanical ventilation. Levels of the vascular growth factor Angiopoietin 2 (Ang2) in plasma have been strongly correlated with increased ARDS risk in patients with pneumonia or sepsis. The intent of this study was to determine whether LY3127804, an anti-Ang2 monoclonal antibody, could reduce the need for mechanical ventilation among patients admitted to the hospital with pneumonia and presumed or confirmed COVID-19.
METHODS: Patients admitted to hospital with confirmed pneumonia, presumed or confirmed COVID-19, and infiltrates on chest imaging and/or oxygen saturation of ≤ 95% on room air were stratified by age group (< 65 years and ≥ 65 years), sex, and site and randomly assigned 1:1 within each stratum to receive either LY3127804 (20 mg/kg) or placebo on Day 1 and possibly on Day 15. The primary end point for this study was number of days in which a patient did not require a ventilator over the 28-day study period. RESULTS: Interim analysis assessed study futility after 95 randomized patients had 28-day data available and showed no benefit of LY3127804 in reducing the number of ventilator days over placebo. The study was subsequently terminated. CONCLUSION: LY3127804 treatment did not decrease the need for ventilator usage in patients hospitalized with pneumonia and presumed or confirmed COVID-19. CLINICALTRIALS.
Data Sharing Statement Lilly provides access to all individual participant data collected during the trial, after anonymization. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org .
ORCID iD Paul H. Berg https://orcid.org/0000-0001-8418-6815
Supplemental Material Supplemental material for this article is available online.
References
Ackermann, Verleden, Kuehnel, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19, N Engl J Med
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19 -final report, N Engl J Med
Calfee, Janz, Bernard, Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies, CHEST
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19, N Engl J Med
Etoh, Inoue, Tanaka, Barnard, Kitano et al., Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases, Cancer Res
Fan, Beitler, Brochard, COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?, Lancet Resp Med
Foxton, Uhles, Grüner, Revelant, Ullmer, Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization, EMBO Mol Med
Gattinoni, Chiumello, Caironi, COVID-19 pneumonia: different respiratory treatments for different phenotypes?, Intensive Care Med
Gattinoni, Coppola, Cressoni, Busana, Rossi et al., COVID-19 does not lead to a "typical" acute respiratory distress syndrome, Am J Respir Crit Care Med
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Gutbier, Neuhauss, Reppe, Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia, Am J Respir Crit Care Med
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet
Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with COVID-19, N Engl J Med
Lomas-Neira, Heffernan, Ayala, Monaghan, Blockade of endothelial growth factor, angiopoietin-2, reduces indices of ards and mortality in mice resulting from the dual-insults of hemorrhagic shock and sepsis, Shock
Marini, Gattinoni, Management of COVID-19 respiratory distress, JAMA
Parikh, Mammoto, Schultz, Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans, PLoS Med
Qi, Li, Hao, Association between angiopoietin-2 and enterovirus 71 induced pulmonary edema, Indian J Pediatr
Salama, Han, Yau, Tocilizumab in patients hospitalized with COVID-19 pneumonia, N Engl J Med
Stiehl, Thamm, Kaufmann, Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis, Crit Care Med
Thompson, Chambers, Liu, Acute respiratory distress syndrome, N Engl J Med
Van Der Heijden, Van Nieuw Amerongen, Koolwijk, Van Hinsbergh, Groeneveld, Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients, Thorax
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19, N Engl J Med
DOI record:
{
"DOI": "10.1177/11795484221119316",
"ISSN": [
"1179-5484",
"1179-5484"
],
"URL": "http://dx.doi.org/10.1177/11795484221119316",
"abstract": "<jats:sec><jats:title>BACKGROUND</jats:title><jats:p> Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring mechanical ventilation. Levels of the vascular growth factor Angiopoietin 2 (Ang2) in plasma have been strongly correlated with increased ARDS risk in patients with pneumonia or sepsis. The intent of this study was to determine whether LY3127804, an anti-Ang2 monoclonal antibody, could reduce the need for mechanical ventilation among patients admitted to the hospital with pneumonia and presumed or confirmed COVID-19. </jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p> Patients admitted to hospital with confirmed pneumonia, presumed or confirmed COVID-19, and infiltrates on chest imaging and/or oxygen saturation of ≤ 95% on room air were stratified by age group (< 65 years and ≥ 65 years), sex, and site and randomly assigned 1:1 within each stratum to receive either LY3127804 (20 mg/kg) or placebo on Day 1 and possibly on Day 15. The primary end point for this study was number of days in which a patient did not require a ventilator over the 28-day study period. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> Interim analysis assessed study futility after 95 randomized patients had 28-day data available and showed no benefit of LY3127804 in reducing the number of ventilator days over placebo. The study was subsequently terminated. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> LY3127804 treatment did not decrease the need for ventilator usage in patients hospitalized with pneumonia and presumed or confirmed COVID-19. </jats:p></jats:sec><jats:sec><jats:title>ClinicalTrials.gov identifier</jats:title><jats:p> NCT04342897 </jats:p></jats:sec>",
"alternative-id": [
"10.1177/11795484221119316"
],
"article-number": "11795484221119316",
"author": [
{
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"family": "Jones",
"given": "Rosie S.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"family": "Smith",
"given": "Patricia S.",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0001-8418-6815",
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"authenticated-orcid": false,
"family": "Berg",
"given": "Paul H.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"family": "de la Peña",
"given": "Amparo",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "East Carolina University Brody School of Medicine, Greenville, NC, USA"
}
],
"family": "Cook",
"given": "Paul P.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Franciscan Alliance, Indianapolis, IN, USA"
}
],
"family": "Shawa",
"given": "Imad",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Franciscan Alliance, Indianapolis, IN, USA"
}
],
"family": "Kioussopoulos",
"given": "Kathleen M.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"family": "Hu",
"given": "Yu",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Eli Lilly and Company, Indianapolis, IN, USA"
}
],
"family": "Schott",
"given": "Robert J.",
"sequence": "additional"
}
],
"container-title": "Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine",
"container-title-short": "Clin Med Insights Circ Respir Pulm Med",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"journals.sagepub.com"
]
},
"created": {
"date-parts": [
[
2022,
8,
11
]
],
"date-time": "2022-08-11T06:29:11Z",
"timestamp": 1660199351000
},
"deposited": {
"date-parts": [
[
2025,
3,
1
]
],
"date-time": "2025-03-01T07:02:37Z",
"timestamp": 1740812557000
},
"funder": [
{
"DOI": "10.13039/100004312",
"doi-asserted-by": "publisher",
"id": [
{
"asserted-by": "publisher",
"id": "10.13039/100004312",
"id-type": "DOI"
}
],
"name": "Eli Lilly and Company"
}
],
"indexed": {
"date-parts": [
[
2025,
11,
1
]
],
"date-time": "2025-11-01T13:57:00Z",
"timestamp": 1762005420880,
"version": "3.41.2"
},
"is-referenced-by-count": 8,
"issued": {
"date-parts": [
[
2022,
1
]
]
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by-nc/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
1,
1
]
],
"date-time": "2022-01-01T00:00:00Z",
"timestamp": 1640995200000
}
}
],
"link": [
{
"URL": "https://journals.sagepub.com/doi/pdf/10.1177/11795484221119316",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journals.sagepub.com/doi/full-xml/10.1177/11795484221119316",
"content-type": "application/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journals.sagepub.com/doi/pdf/10.1177/11795484221119316",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "179",
"original-title": [],
"prefix": "10.1177",
"published": {
"date-parts": [
[
2022,
1
]
]
},
"published-online": {
"date-parts": [
[
2022,
8,
10
]
]
},
"published-print": {
"date-parts": [
[
2022,
1
]
]
},
"publisher": "SAGE Publications",
"reference": [
{
"DOI": "10.1056/NEJMoa2002032",
"doi-asserted-by": "publisher",
"key": "bibr1-11795484221119316"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"doi-asserted-by": "publisher",
"key": "bibr2-11795484221119316"
},
{
"DOI": "10.1001/jama.2020.1585",
"doi-asserted-by": "publisher",
"key": "bibr3-11795484221119316"
},
{
"DOI": "10.1056/NEJMra1608077",
"doi-asserted-by": "publisher",
"key": "bibr4-11795484221119316"
},
{
"DOI": "10.1101/2020.02.17.20024166",
"doi-asserted-by": "publisher",
"key": "bibr5-11795484221119316"
},
{
"DOI": "10.1164/rccm.202003-0817LE",
"doi-asserted-by": "publisher",
"key": "bibr6-11795484221119316"
},
{
"DOI": "10.1007/s00134-020-06033-2",
"doi-asserted-by": "publisher",
"key": "bibr7-11795484221119316"
},
{
"DOI": "10.1001/jama.2020.6825",
"doi-asserted-by": "publisher",
"key": "bibr8-11795484221119316"
},
{
"DOI": "10.1016/S2213-2600(20)30304-0",
"doi-asserted-by": "publisher",
"key": "bibr9-11795484221119316"
},
{
"key": "bibr10-11795484221119316",
"unstructured": "WHO Coronavirus (COVID-19) Dashboard. Accessed March 01, 2021. https://covid19.who.int/"
},
{
"DOI": "10.1056/NEJMoa2015432",
"doi-asserted-by": "publisher",
"key": "bibr11-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2007764",
"doi-asserted-by": "publisher",
"key": "bibr12-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2029849",
"doi-asserted-by": "publisher",
"key": "bibr13-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2035002",
"doi-asserted-by": "publisher",
"key": "bibr14-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2031994",
"doi-asserted-by": "publisher",
"key": "bibr15-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2021436",
"doi-asserted-by": "publisher",
"key": "bibr16-11795484221119316"
},
{
"DOI": "10.1056/NEJMoa2030340",
"doi-asserted-by": "publisher",
"key": "bibr17-11795484221119316"
},
{
"DOI": "10.1097/SHK.0000000000000499",
"doi-asserted-by": "publisher",
"key": "bibr18-11795484221119316"
},
{
"DOI": "10.15252/emmm.201810204",
"doi-asserted-by": "publisher",
"key": "bibr19-11795484221119316"
},
{
"author": "Etoh T",
"first-page": "2145",
"issue": "5",
"journal-title": "Cancer Res",
"key": "bibr20-11795484221119316",
"volume": "61",
"year": "2001"
},
{
"DOI": "10.1164/rccm.201708-1733OC",
"doi-asserted-by": "publisher",
"key": "bibr21-11795484221119316"
},
{
"DOI": "10.1371/journal.pmed.0030046",
"doi-asserted-by": "publisher",
"key": "bibr22-11795484221119316"
},
{
"DOI": "10.1007/s12098-015-1920-2",
"doi-asserted-by": "publisher",
"key": "bibr23-11795484221119316"
},
{
"DOI": "10.1136/thx.2007.087387",
"doi-asserted-by": "publisher",
"key": "bibr24-11795484221119316"
},
{
"DOI": "10.1097/CCM.0000000000000524",
"doi-asserted-by": "publisher",
"key": "bibr25-11795484221119316"
},
{
"DOI": "10.1378/chest.14-2454",
"doi-asserted-by": "publisher",
"key": "bibr26-11795484221119316"
},
{
"DOI": "10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7",
"doi-asserted-by": "publisher",
"key": "bibr27-11795484221119316"
},
{
"key": "bibr28-11795484221119316",
"unstructured": "Adaptive COVID-19 Treatment Trial (ACTT), Identifier NCT04280705. Bethesda (MD): National Library of Medicine (US). Updated April 12, 2021. https://clinicaltrials.gov/ct2/show/NCT04280705"
},
{
"key": "bibr29-11795484221119316",
"unstructured": "WHO R&D Blueprint Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis. Accessed April 12, 2021. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf"
}
],
"reference-count": 29,
"references-count": 29,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.sagepub.com/doi/10.1177/11795484221119316"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19",
"type": "journal-article",
"update-policy": "https://doi.org/10.1177/sage-journals-update-policy",
"updated-by": [
{
"DOI": "10.1177/11795484221127555",
"label": "Correction",
"source": "publisher",
"type": "correction",
"updated": {
"date-parts": [
[
2022,
12,
13
]
],
"date-time": "2022-12-13T00:00:00Z",
"timestamp": 1670889600000
}
}
],
"volume": "16"
}
